BIOMARKERS FOR EARLY SEPSIS DETECTION
With
Dr Gabrielle Briggs
Postdoctoral Researcher and Lab Manager,
School of Medicine and Public Health
The University of Newcastle, New South Wales, Australia
RESEARCHER PROFILE
Filmed in Newcastle, New South Wales, Australia | October 2025
Dr Gabrielle Briggs is a biomedical scientist dedicated to finding smarter, faster ways to diagnose and treat life threatening complications in critically ill patients. Dr Briggs established a research laboratory embedded within the John Hunter Hospital – one of the busiest major trauma centres in NSW. Dr Briggs works alongside surgeons, intensivists, and pathologists to turn complex clinical problems into practical research solutions. Her work spans two major programs: developing a rapid diagnostic test to detect bacterial infections in blood before sepsis takes hold, and exploring mitochondrial transplantation as a novel therapy to rescue injured tissues after trauma and ischaemia.
Dr Briggs has a strong focus on innovation and translation, building close partnerships between the university and the health service to accelerate the movement of new technologies into clinical practice. Gabrielle played a key role in founding the Hunter Medical Research Institute’s Injury and Trauma Research Program and currently serves as its Deputy Director. Gabrielle is also an enthusiastic educator, teaching the next generation of clinicians in the University of Newcastle’s Joint Medical Program.
Source: Supplied
https://orcid.org/0000-0002-9117-4772
-
Genomics and rationally targeted therapies in Acute Lymphoblastic Leukaemia
Prof Deborah White’s research focus is genomics and rationally targeted therapies in Acute Lymphoblastic Leukaemia (ALL) and Chronic Myeloid Leukaemia (CML) and she holds peer reviewed grants from: The William Lawrence and Blanche Hughes Foundation and the Leukemia Lymphoma Society (USA), the NHMRC, the Leukaemia Foundation Australia (LFA), Channel 7, Cancer Australia, Tour de Cure and the Cancer Council SA (CCSA). Professor White has presented more than 170 papers at scientific meetings, and authored more than 100 scientific publications as well as being an inventor on several international patents.
-
Pancreatic and lung cancers driven by mutations in the cancer gene KRAS
Dr Mara Zeissig is a recently appointed Lab Head within the Tumour Inflammation and Immunotherapy Program at the South Australian immunoGENomics Cancer Institute (SAiGENCI).
Her research focuses on studying immune evasion mechanisms in lung and pancreatic cancers to identify novel ways to increase response to immunotherapy. Her expertise is in genetically engineered mouse models of lung cancer, CRISPR-Cas9 screening technologies and T cell based immunotherapies (e.g Checkpoint inhibitors). -
Superslayer taking on antibiotic-resistant bacteria
Dr Katharina Richter is a visionary leader in MedTech, acclaimed for innovation and gender diversity. With over 40 awards to her name, including MIT Innovator Under 35 Asia-Pacific, and Prime Minister’s Prize for New Innovator finalist, she has shattered barriers as an entrepreneur, scientist, and ‘superbug slayer.’ Katharina’s groundbreaking work in combating antibiotic-resistant bacteria has resulted in 6 innovative treatments, 3 of which are patented, offering hope against deadly infections.
